Markel Stacy sold $753K of NUVB
Markel Stacy (CHIEF PEOPLE OFFICER) sold 125,000 shares of Nuvation Bio Inc. (NUVB) at $6.03 ($0.75M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the reported open-market sale size, price, and post-transaction holdings by the company’s Chief People Officer, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 structure generally limits immediate fundamental interpretation.
What to watch
Insider sales can still matter if they cluster with other insider selling or coincide with deteriorating fundamentals; this brief contains only one transaction and no context on prior insider activity.
Background
The article is a SEC Form 4 insider transaction disclosure for Nuvation Bio Inc. (NUVB).
Ticker impact
NUVB disclosed a Form 4 showing Markel Stacy (Chief People Officer) sold 125,000 shares at $6.0255 on 2026-06-23 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this filing; any reaction would be modest and short-lived.
The filing is primary-source and company-specific, but the transaction is an open-market sale executed under a Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-through; this is a single-company insider transaction.
None.
None.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerNuvation Bio Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderMarkel Stacy
Chief People Officer who sold 125,000 shares under a 10b5-1 plan.
